By Michael Erman SAN FRANCISCO, Feb 11 (Reuters) - Some pharmaceutical companies not targeted by President Donald Trump for ...

With big pharma signalling interest in novel RNA-targeted approaches, the term “druggable” is being redefined as technology ...

According to multiple recent market analyses, the global API market is experiencing steady growth. One comprehensive forecast projects the global active pharmaceutical ingredient market to expand from ...

Andreas Eschbach is the founder and CEO of eschbach, a software company that helps production teams work smarter and enhance collaboration. The pharmaceutical industry stands at a critical juncture.

Health Affairs' Jeff Byers welcomes Stacie Dusetzina of Vanderbilt University Medical Center and David Simon of the University of Connecticut back to the pod to the current state of drug prices, how ...

To understand what China's fast-developing drug industry might mean for global pharmaceutical companies, look no further than the market for GLP-1 drugs.

Opening up about drug pricing decisions is not optional for biopharma anymore. For the sake of credibility, companies should embrace it.

When President Donald Trump announced 10% global tariffs in April, the pharma industry remained largely unscathed. However, the president has since threatened to slap additional tariffs on ...

BridgeBio Pharma’s experimental drug for the most common cause of dwarfism accelerated children’s growth in a pivotal clinical trial.

“Affordability” is the watchword in American politics today. Inflation is squeezing families, but nothing hits harder than the cost of trying to stay alive. Yet as patients weigh whether they can ...

Aging means “becoming a target” of the industry, one expert said. After decades of debate, politicians of all stripes are ...